drugset / Trial / NCT04803877
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
NaSingle-groupOpen-labelTreatment
Summary
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Timeline
- Start
- 2021-06-04
- Primary completion
- 2025-11
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Regorafenib | Small molecule | 60 mg/m2 | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |